In the latest quarter, 17 analysts provided ratings for Crinetics Pharmaceuticals CRNX, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 9 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 5 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 5 | 4 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Crinetics Pharmaceuticals, revealing an average target of $64.06, a high estimate of $97.00, and a low estimate of $50.00. This current average reflects an increase of 18.45% from the previous average price target of $54.08.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Crinetics Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | $60.00 |
| Brian Skorney | Baird | Raises | Outperform | $62.00 | $52.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $70.00 | $50.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $65.00 | $65.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $60.00 | - |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | - |
| Yasmeen Rahimi | Piper Sandler | Raises | Overweight | $97.00 | $56.00 |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | - |
| Leland Gershell | Oppenheimer | Raises | Outperform | $55.00 | $54.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $80.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $60.00 | $50.00 |
| Lina Kaminski | JonesTrading | Raises | Buy | $56.00 | $52.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $50.00 | - |
| Leland Gershell | Oppenheimer | Raises | Outperform | $54.00 | $48.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $50.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $50.00 | $42.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crinetics Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crinetics Pharmaceuticals compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Crinetics Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Crinetics Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Crinetics Pharmaceuticals analyst ratings.
Discovering Crinetics Pharmaceuticals: A Closer Look
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Crinetics Pharmaceuticals's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Crinetics Pharmaceuticals's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -76.11% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Crinetics Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10457.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crinetics Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.47%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Crinetics Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -8.3%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Crinetics Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
